Published 4th November 2016

Inivata enters partnership with N-of-One

>N-of-One to Identify Treatment Strategies and Clinical Trial Opportunities for Patients based on Inivata’s ctDNA Liquid Biopsy Analysis.

Portfolio company Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, and N-of-One, Inc., a precision medicine oncology decision support company, have announced a new partnership to support analysis of patient cases for Inivata’s InVision® liquid biopsy product line. This partnership will enable the delivery of clear, easy to interpret patient reports, providing physicians with a wealth of genomic information at their fingertips.

Michael Stocum, Ceo of Inivata, said:

“N-of-One’s experience in curating complex genomic information and translating this data into clinically relevant results on tens of thousands of patients has enabled them to develop a market-leading database and unparalleled expertise. We are excited to access their capabilities to ensure we provide physicians with the most actionable information in our easy to interpret report”

Learn more

Press contacts